Comment on Media Report

Rhea-AI Summary

Evotec SE has received an unsolicited, non-binding expression of interest from US biotechnology company Halozyme Therapeutics Inc. regarding a potential takeover. The proposed offer price is EUR 11.00 per share. Evotec states that there was no prior contact before this expression of interest. The company will analyze the proposal and inform the capital market about next steps in accordance with legal requirements.

Positive

• Potential takeover offer at EUR 11.00 per share indicates market interest in the company
• Interest from established US biotech company could lead to strategic opportunities

Negative

• Unsolicited nature of the offer might indicate lack of alignment with company's strategic plans
• Non-binding status creates uncertainty for shareholders

Insights

M&A Analyst

This unsolicited takeover interest from Halozyme at €11.00 per share represents a significant development for Evotec. The offer implies a premium to recent trading prices and values Evotec at approximately €1.9 billion. Halozyme's interest likely stems from Evotec's strong drug discovery platform and partnerships with major pharmaceutical companies.

The non-binding nature of the expression of interest means there's no certainty of a deal materializing. Key considerations for Evotec's board will include valuation adequacy, strategic fit and potential synergies. Halozyme's ENHANZE drug delivery technology could complement Evotec's drug discovery capabilities, potentially creating a more comprehensive drug development platform.

Shareholders should note that this is very preliminary and the board has significant fiduciary duties to evaluate any proposal thoroughly. The lack of prior contact suggests this could be the opening move in what might become a longer negotiation process.

HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.

Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com

SOURCE: Evotec SE

View the original press release on accesswire.com

FAQ

What is the proposed takeover price per share for Evotec (EVO) by Halozyme?

Halozyme Therapeutics has proposed a takeover offer price of EUR 11.00 per share for Evotec SE.

Is Halozyme's takeover offer for Evotec (EVO) binding?

No, Halozyme's expression of interest is non-binding at this stage.

When did Evotec (EVO) receive the takeover interest from Halozyme?

Evotec received the unsolicited expression of interest from Halozyme Therapeutics as reported on November 14, 2024.

How did Evotec (EVO) respond to Halozyme's takeover interest?

Evotec stated they will carefully analyze the expression of interest, decide on next steps, and inform the capital market according to legal requirements.